| # | Title | Journal | Year | Citations |
|---|
| 1 | CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death | Nature | 2005 | 547 |
| 2 | Management of stage T1 tumors of the bladder: International Consensus Panel | Urology | 2005 | 371 |
| 3 | Platelet-Mediated Modulation of Adaptive Immunity | Immunity | 2003 | 353 |
| 4 | Extent of Pelvic Lymphadenectomy and Its Impact On Outcome in Patients Diagnosed With Bladder Cancer: Analysis of Data From the Surveillance, Epidemiology and End Results Program Data Base | Journal of Urology | 2003 | 310 |
| 5 | Report of Four Cases | Fertility and Sterility | 1954 | 282 |
| 6 | Fertilizing Capacity of Frozen Human Spermatozoa | Nature | 1953 | 257 |
| 7 | Life Stress, Mood Disturbance, and Elevated Interleukin-6 in Healthy Older Women | Journals of Gerontology - Series A Biological Sciences and Medical Sciences | 1999 | 247 |
| 8 | Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆ | Urologic Oncology: Seminars and Original Investigations | 2006 | 217 |
| 9 | Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles | Blood | 2008 | 210 |
| 10 | Training, Credentialing, Proctoring and Medicolegal Risks of Robotic Urological Surgery: Recommendations of the Society of Urologic Robotic Surgeons | Journal of Urology | 2009 | 196 |
| 11 | NK cells are essential for effective BCG immunotherapy | International Journal of Cancer | 2001 | 194 |
| 12 | Durable oncologic outcomes after radiofrequency ablation | Cancer | 2010 | 194 |
| 13 | IMPACT OF HOSPITAL AND SURGEON VOLUME ON IN-HOSPITAL MORTALITY FROM RADICAL CYSTECTOMY: DATA FROM THE HEALTH CARE UTILIZATION PROJECT | Journal of Urology | 2005 | 192 |
| 14 | Effect of Amitriptyline on Symptoms in Treatment Naïve Patients With Interstitial Cystitis/Painful Bladder Syndrome | Journal of Urology | 2010 | 174 |
| 15 | Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial | Lancet Oncology, The | 2021 | 172 |
| 16 | Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand | Cancer Research | 2004 | 167 |
| 17 | TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies | European Journal of Pharmacology | 2009 | 163 |
| 18 | The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer | European Urology | 2010 | 160 |
| 19 | Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients | Brain, Behavior, and Immunity | 2011 | 159 |
| 20 | Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancer | Cancer | 2015 | 157 |
| 21 | The emerging role of platelets in adaptive immunity | Cellular Immunology | 2005 | 148 |
| 22 | Intravesical Treatments of Bladder Cancer: Review | Pharmaceutical Research | 2008 | 142 |
| 23 | Stress and symptoms in patients with interstitial cystitis: a life stress model | Urology | 2001 | 141 |
| 24 | Factors Influencing Aggressive Therapy for Bladder Cancer: An Analysis of Data From the SEER Program | Journal of Urology | 2003 | 135 |
| 25 | Management of Functional Constipation in Children with Lower Urinary Tract Symptoms: Report from the Standardization Committee of the International Children's Continence Society | Journal of Urology | 2013 | 135 |
| 26 | Squamous cell carcinoma of the penis | Cancer | 2004 | 133 |
| 27 | The MAPP research network: design, patient characterization and operations | BMC Urology | 2014 | 128 |
| 28 | Risk Factors for Erosion of Artificial Urinary Sphincters: A Multicenter Prospective Study | Urology | 2014 | 124 |
| 29 | The MAPP research network: a novel study of urologic chronic pelvic pain syndromes | BMC Urology | 2014 | 123 |
| 30 | Quality of life in long-term survivors of bladder cancer | Cancer | 2006 | 115 |
| 31 | Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide | | 1998 | 112 |
| 32 | Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L | Blood | 2005 | 112 |
| 33 | Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review | European Urology | 2018 | 112 |
| 34 | EFFECT OF EXOGENOUS TESTOSTERONE ON PROSTATE VOLUME, SERUM AND SEMEN PROSTATE SPECIFIC ANTIGEN LEVELS IN HEALTHY YOUNG MEN | Journal of Urology | 1998 | 107 |
| 35 | Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer | Journal of Urology | 2010 | 107 |
| 36 | Bladder Cancer Immunotherapy: BCG and Beyond | Advances in Urology | 2012 | 104 |
| 37 | Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer | Journal of Urology | 2013 | 101 |
| 38 | Molecular markers in bladder cancer: A critical appraisal | Urologic Oncology: Seminars and Original Investigations | 2006 | 100 |
| 39 | Role of neutrophils in BCG immunotherapy for bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2008 | 100 |
| 40 | CELL DEATH AND IMMUNE PRIVILEGE | International Reviews of Immunology | 2002 | 95 |
| 41 | TRAIL: A Mechanism of Tumor Surveillance in an Immune Privileged Site | Journal of Immunology | 2002 | 95 |
| 42 | Human B Cells Express Functional TRAIL/Apo-2 Ligand after CpG-Containing Oligodeoxynucleotide Stimulation | Journal of Immunology | 2004 | 95 |
| 43 | Interstitial cystitis/bladder pain syndrome: The evolving landscape, animal models and future perspectives | International Journal of Urology | 2020 | 93 |
| 44 | Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis | Cancer | 2013 | 92 |
| 45 | Urological Injury and Assessment in Patients with Fractured Pelvis | Journal of Urology | 1984 | 90 |
| 46 | Suppression of Tumor Growth Following Intralesional Therapy with TRAIL Recombinant Adenovirus | Molecular Therapy | 2001 | 90 |
| 47 | Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer | Journal of Urology | 2020 | 90 |
| 48 | Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2014 | 89 |
| 49 | THE IMPACT OF PROVIDER VOLUME ON OUTCOMES FROM UROLOGICAL CANCER THERAPY | Journal of Urology | 2005 | 88 |
| 50 | Impact of Previous Bacille Calmette-Guérin Failure Pattern on Subsequent Response to Bacille Calmette-Guérin Plus Interferon Intravesical Therapy | Urology | 2008 | 88 |
